Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-10-30
DOI
https://doi.org/10.3389/fimmu.2025.1704239
Citations
1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
1.32
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy

Hongwei Xu, Yonggang Wei, Haili Zhang, Tongshu Yang et al.
1 citations
Frontiers in Immunology
Hepatocellular Carcinoma Treatment and Prognosis
1.32
article

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy

Hongwei Xu, Yonggang Wei, Haili Zhang, Tongshu Yang, Lüping Huang, Bo Li
article en
1 citations

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
Army Medical University (CN), Sichuan University (CN), West China Hospital of Sichuan University (CN), Sichuan Cancer Hospital (CN), Southwest Hospital (CN)
Openalex Percentile: Top 15%
Hepatocellular Carcinoma Treatment and Prognosis
1.32
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Tumor regression grade predicts recurrence-free survival in intermediate-advanced hepatocellular carcinoma after conversion therapy — Hongwei Xu, Yonggang Wei, et al. · Frontiers in Immunology (2025) | TGRS Research Map | TGRS